Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Moderna's Quarterly Earnings Preview: What You Need to Know

 Valued at a market cap of $21.2 billion, Moderna, Inc. (MRNA) is a biotechnology company that pioneered the use of messenger RNA (mRNA) therapeutics and vaccines to transform how medicines are created. The Cambridge, Massachusetts-based company is expected to announce its fiscal Q1 earnings for 2026 before the market opens on Friday, May 1. 

Ahead of this event, analysts expect this biotechnology company to report a loss of $2.27 per share, down 9.9% from a loss of $2.52 per share in the year-ago quarter. The company has topped Wall Street’s bottom-line estimates in each of the last four quarters. In Q4 2025, Moderna’s...

Fundamentals

See More
  • Market Capitalization, $K 929,557
  • Shares Outstanding, K 196,940
  • Annual Sales, $ 14,080 K
  • Annual Income, $ -33,500 K
  • EBIT $ -38 M
  • EBITDA $ -38 M
  • 60-Month Beta 0.74
  • Price/Sales 65.45
  • Price/Cash Flow N/A
  • Price/Book 11.75

Options Overview Details

View History
  • Implied Volatility 80.19% (+3.71%)
  • Historical Volatility 49.36%
  • IV Percentile 27%
  • IV Rank 4.97%
  • IV High 603.85% on 01/14/26
  • IV Low 52.83% on 08/13/25
  • Expected Move (DTE 25) 0.13 (2.75%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 391
  • Volume Avg (30-Day) 494
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 15,683
  • Open Int (30-Day) 18,945
  • Expected Range 4.51 to 4.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) +768,561.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.13 +12.47%
on 04/13/26
4.75 -2.21%
on 04/17/26
+0.41 (+9.55%)
since 03/20/26
3-Month
3.50 +32.71%
on 02/02/26
4.85 -4.15%
on 03/10/26
+0.44 (+10.46%)
since 01/20/26
52-Week
2.94 +57.99%
on 05/15/25
5.10 -8.92%
on 09/11/25
+1.49 (+47.46%)
since 04/17/25

Most Recent Stories

More News
Moderna's Quarterly Earnings Preview: What You Need to Know

Moderna is expected to announce its fiscal first-quarter earnings next month, and analysts project a high single-digit decline in losses.

ABUS : 4.64 (-1.69%)
XLV : 148.07 (-0.49%)
$SPX : 7,106.01 (-0.28%)
MRNA : 54.65 (+1.73%)
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:...

ABUS : 4.64 (-1.69%)
Arbutus: Q4 Earnings Snapshot

Arbutus: Q4 Earnings Snapshot

ABUS : 4.64 (-1.69%)
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery...

ABUS : 4.64 (-1.69%)
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized,...

ABUS : 4.64 (-1.69%)
ROIVW : 2.75 (-3.85%)
ROIV : 29.47 (-1.21%)
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized,...

ABUS : 4.64 (-1.69%)
ROIV : 29.47 (-1.21%)
Arbutus: Q3 Earnings Snapshot

Arbutus: Q3 Earnings Snapshot

ABUS : 4.64 (-1.69%)
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $93.7M     Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling...

ABUS : 4.64 (-1.69%)
Arbutus Biopharma Showcases Data at Liver Meeting 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Arbutus Biopharma...

ABUS : 4.64 (-1.69%)
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Multiple abstracts accepted featuring imdusiran clinical data  – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as...

ABUS : 4.64 (-1.69%)

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 4.93
2nd Resistance Point 4.84
1st Resistance Point 4.78
Last Price 4.64
1st Support Level 4.63
2nd Support Level 4.54
3rd Support Level 4.48

See More

52-Week High 5.10
Last Price 4.64
Fibonacci 61.8% 4.27
Fibonacci 50% 4.02
Fibonacci 38.2% 3.77
52-Week Low 2.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.